From: Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours
 | Combined NER | ||||
---|---|---|---|---|---|
Variable | N | Mean HS | SEM | Median | p value |
All patients | 207 | 282.6 | 10.1 | 280.0 | NA |
Histology | |||||
 Seminoma | 38 | 202.2 | 22.9 | 205.0 | ***0.0004 |
 Non-seminoma | 169 | 300.6 | 10.8 | 300.0 |  |
Tumour primary | |||||
 Primary TGCTs | 200 | 279.9 | 10.2 | 270.0 | *0.0500 |
 Extragonadal GCTs | 7 | 387.0 | 63.4 | 360.0 |  |
IGCCCG risk group | |||||
 Good prognosis | 158 | 266.4 | 11.3 | 260.0 | **0.0062 |
 Intermediate | 23 | 321.3 | 29.1 | 320.0 |  |
 Poor prognosis | 26 | 358.3 | 30.4 | 345.0 |  |
Number of metastatic sites | |||||
 0 | 54 | 279.0 | 19.2 | 250.0 | *0.0471 |
 1 to 2 | 124 | 271.0 | 12.9 | 270.0 |  |
  > 3 | 29 | 348.3 | 28.8 | 330.0 |  |
Retroperitoneal lymph nodes metastases | |||||
 Absent | 61 | 282.7 | 18.3 | 250.0 | 0.6121 |
 Present | 146 | 282.5 | 12.2 | 287.5 |  |
Mediastinal lymph nodes metastases | |||||
 Absent | 189 | 277.9 | 10.5 | 270.0 | 0.1142 |
 Present | 18 | 339.7 | 36.6 | 310.0 |  |
Lung metastases | |||||
 Absent | 160 | 268.8 | 11.3 | 252.5 | ***0.0048 |
 Present | 47 | 331.9 | 21.4 | 325.0 |  |
Liver | |||||
 Absent | 197 | 278.5 | 10.3 | 270.0 | 0.0584 |
 Present | 10 | 368.3 | 47.1 | 350.0 |  |
Non-pulmonary visceral metastases | |||||
 Absent | 194 | 278.3 | 10.4 | 270.0 | 0.0661 |
 Present | 13 | 354.5 | 42.7 | 345.0 |  |
S stage | |||||
 0 | 78 | 246.7 | 15.5 | 232.5 | ***0.0004 |
 1 | 78 | 283.1 | 15.8 | 285.0 |  |
 2 | 29 | 335.0 | 26.3 | 345.0 |  |
 3 | 16 | 385.7 | 36.5 | 362.5 |  |
 unknown | 6 |  |  |  |  |